Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.

Khan, Husain Yar; Nagasaka, Misako; Aboukameel, Amro; Alkhalili, Osama; Uddin, Md Hafiz; Bannoura, Sahar; Mzannar, Yousef; Azar, Ibrahim; Beal, Eliza; Tobon, Miguel; Kim, Steve; Beydoun, Rafic; Baloglu, Erkan; Senapedis, William; El-Rayes, Bassel; Philip, Philip A; Mohammad, Ramzi M; Shields, Anthony F; Al-Hallak, Mohammed Najeeb; Azmi, Asfar S

Khan, Husain Yar; Nagasaka, Misako; Aboukameel, Amro; Alkhalili, Osama; Uddin, Md Hafiz; Bannoura, Sahar; Mzannar, Yousef; Azar, Ibrahim; Beal, Eliza; Tobon, Miguel; Kim, Steve; Beydoun, Rafic; Baloglu, Erkan; Senapedis, William; El-Rayes, Bassel; Philip, Philip A; Mohammad, Ramzi M; Shields, Anthony F; Al-Hallak, Mohammed Najeeb; Azmi, Asfar S.

bioRxiv ; 2023 Mar 27.

Article in En | MEDLINE | ID: mdl-37034616

Fulltext

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081231
https://dx.doi.org/10.1101/2023.03.27.534309

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2023 Type: Article

Fulltext

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081231
https://dx.doi.org/10.1101/2023.03.27.534309

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2023 Type: Article